- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01809912
Safety Study of MG1102 in Patients With Solid Tumors
A PHASE 1, OPEN LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MG1102 IN PATIENTS WITH SOLID TUMORS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, Dose Escalation Study, multicenter phase I study to evaluate the safety and tolerability, determine the pharmacokinetics, and obtain preliminary information regarding pharmacodynamics and efficacy of MG1102 in subjects with solid tumor.
Each subject will receive on dose of MG1102 followed by a 6-day rest period. If the initial dose is tolerated, subject will continue with the 21 days of MG1102 administration (5 days on treatment, 2 days off treatment for 3 weeks.) Subjects that have a tumor response as stable disease, may continue therapy on a compassionate use.
Study Duration : for a minimum of 8 weeks
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Yonsei Cancer Center, Yonsei University Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- Solid tumors refractory to conventional therapy or the subject does not tolerate the conventional therapy
- Evaluable disease or at least one measurable tumor mass by a radiographic technique
- Life expectancy ≥3 months
- Suitable for intravenous administration of study medication
- Signed written informed consent
- Adequate bone marrow, renal, and liver function
- Coagulation profile with aPTT and INR, each ≤ 1.5 x ULN
- No evidence of active Hepatitis B or Hepatitis C infection
- Proteinuria <100 mg
- ECOG performance status ≤2
- Female subjects must agree to use contraceptive measures
- Negative serum ß-hCG
- Ability and willingness to comply with the study protocol
Exclusion Criteria:
- Pregnant or lactating women
- Therapy with systemic anticoagulant or antithrombotic agentswithin 7 days prior to first dose
- Hemoptysis within 3 months prior to first dose
- Cytotoxic chemotherapy, immunotherapy, or radiotherapy within 4 weeks prior to first dose
- Surgery or visceral biopsy within 28 days prior to first dose
- Minor surgical procedure performed within 7 days prior to first dose
- Prior exposure to MG1102
- Known history of HIV
- With active bacterial infections and/or receiving systemic antibiotics
- Current or past diagnosis of leukemia
- Known CNS metastases or clinical evidence of CNS
- Non-healing wound within past 2 weeks
- Bleeding diathesis or bleeding within 14 days prior to enrollment
- Clinically significant thrombosis
- Non-malignant GI bleeding, gastric stress ulcerations, or peptic ulcer disease
- History of idiopathic or hereditary angioedema
- History of sickle cell or any hemolytic anemia
- Require hemoglobin, WBC, or platelet transfusion support or use of hematopoietic growth factors within 2 weeks prior to entry
- Uncontrolled hypertension
- History of clinically significant renal disease
- History of significant medical illness of cardiac or CNS disease within the past 6 months
- Treatment with an investigational agent within the longest time frame of either 5 half-lives or 30 days of initiating study drug
- Medical or psychiatric illness
- Recreational substance use or psychiatric illness
- Known hypersensitivity to MG1102 or components of the formulation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Greenstatin
Cohort 1 : 6 mg/m2 Cohort 2 : 12 mg/m2 Cohort 3 : 24 mg/m2 Cohort 4 : 48 mg/m2 Cohort 5 : 96 mg/m2 Cohort 6 : 192 mg/m2 28 Day Course Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0. If no DLTs are observed during the 6 days following the initial infusion, the same dose will be administered once daily for 5 consecutive days followed by a 2-day rest period three times (over 21 days), completing the course on Day 27. Additional 21 Day Courses In the absence of a DLT, and in the case of stable disease or better, a subject may continue to receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) on a compassionate use basis at the same dose and regimen . |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To investigate the safety and tolerability IV MG1102
Time Frame: A minimum of 9 weeks
|
Adverse events, physical examinations, vital signs, ECGs, clinical laboratory evaluations, lipid profiles
|
A minimum of 9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Each subject's serum drug concentration-time data to determine the pharmacokinetic profile of MG1102
Time Frame: for 25 days
|
for 25 days
|
standard clinical serum tumor markers via serum samples to obtain preliminary information regarding the pharmacodynamics of MG1102
Time Frame: A minimum of 10 weeks
|
A minimum of 10 weeks
|
Determination of response assessed by RECIST v1.1 and Choi criteria to obtain preliminary information regarding the efficacy of MG1102
Time Frame: A minimum of 11 weeks
|
A minimum of 11 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: hyunchul chung, dr, Yonsei Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
Clinical Trials on Recombinant human apolipoprotein(a) Kringle V
-
CSL BehringCompletedAcute Coronary SyndromeUnited States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvi... and more
-
Bio Sidus SARecruiting
-
ShireTakeda Development Center Americas, Inc.Active, not recruitingMetachromatic Leukodystrophy (MLD)Denmark, Germany, Japan, Australia, France, Brazil, Czechia
-
ShireCompletedMetachromatic Leukodystrophy (MLD)Australia, Denmark, Japan, France, Germany
-
ShireCompletedLate Infantile Metachromatic LeukodystrophyDenmark
-
ProtalixChiesi Farmaceutici S.p.A.CompletedFabry DiseaseUnited States, Denmark, Belgium, United Kingdom, Norway, Italy, Czechia
-
ProtalixChiesi Farmaceutici S.p.A.CompletedFabry DiseaseUnited States, Serbia, Spain, United Kingdom, Australia, Paraguay
-
ShireTakeda Development Center Americas, Inc.Active, not recruitingMetachromatic Leukodystrophy (MLD)United States, Canada, Belgium, Israel, Netherlands, United Kingdom, Germany, Spain, Japan, Brazil, Argentina, France, Greece, Italy
-
ProtalixWithdrawn
-
Greenovation Biotech GmbHFGK Clinical Research GmbHCompleted